1-4 of 4
mucopolysaccharidosis vi
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Diagnosis of Attenuated Mucopolysaccharidosis VI: Clinical, Biochemical, and Genetic Pitfalls

Filippo Pinto e Vairo, MD, Erin Conboy, MD, Carolina Fischinger Moura de Souza, MD, Amie Jones, MD, Sarah S. Barnett, MS ...
Pediatrics (2018) 142 (6): e20180658.
Published: December 2018
View article
PDF
Journal Articles

Successful Management of Difficult Infusion-Associated Reactions in a Young Patient With Mucopolysaccharidosis Type VI Receiving Recombinant Human Arylsulfatase B (Galsulfase [Naglazyme])

Katherine H. Kim, MS, Celeste Decker, MD, Barbara K. Burton, MD
Pediatrics (2008) 121 (3): e714–e717.
Published: March 2008
View article
PDF
Journal Articles

Management Guidelines for Mucopolysaccharidosis VI

Roberto Giugliani, MD, PhD, Paul Harmatz, MD, James E. Wraith, MD
Pediatrics (2007) 120 (2): 405–418.
Published: August 2007
View article
PDF
Journal Articles

Direct Comparison of Measures of Endurance, Mobility, and Joint Function During Enzyme-Replacement Therapy of Mucopolysaccharidosis VI (Maroteaux-Lamy Syndrome): Results After 48 Weeks in a Phase 2 Open-Label Clinical Study of Recombinant Human N-Acetylgalactosamine 4-Sulfatase

Paul Harmatz, MD, David Ketteridge, MBBS, Roberto Giugliani, MD, PhD, Natalie Guffon, MD, Elisa Leão Teles, MD ...
Pediatrics (2005) 115 (6): e681–e689.
Published: June 2005
View article
PDF